Protalex Stock Price, News & Analysis (OTCMKTS:PRTX)

$0.54 +0.04 (+8.00 %)
(As of 02/20/2018 12:50 PM ET)
Previous Close$0.50
Today's Range$0.54 - $0.54
52-Week Range$0.31 - $3.00
Volume1,000 shs
Average Volume1,762 shs
Market Capitalization$12.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29

About Protalex (OTCMKTS:PRTX)

Protalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.

Receive PRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PRTX
CUSIPN/A
Phone215-862-9720

Debt

Debt-to-Equity RatioN/A
Current Ratio0.02%
Quick Ratio0.02%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.76) per share
Price / Book-0.71

Profitability

Trailing EPSN/A
Net Income$-4,560,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-815.60%

Miscellaneous

Employees2
Outstanding Shares28,770,000

Protalex (OTCMKTS:PRTX) Frequently Asked Questions

What is Protalex's stock symbol?

Protalex trades on the OTCMKTS under the ticker symbol "PRTX."

How were Protalex's earnings last quarter?

Protalex Inc. (OTCMKTS:PRTX) released its earnings results on Wednesday, October, 11th. The company reported ($0.04) earnings per share for the quarter. View Protalex's Earnings History.

Who are some of Protalex's key competitors?

Who are Protalex's key executives?

Protalex's management team includes the folowing people:

  • Arnold P. Kling, President, Director (Age 57)
  • Kirk M. Warshaw, Chief Financial Officer, Secretary, Director (Age 57)
  • Marco M. Elser, Independent Director (Age 58)

How do I buy Protalex stock?

Shares of Protalex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalex's stock price today?

One share of Protalex stock can currently be purchased for approximately $0.54.

How big of a company is Protalex?

Protalex has a market capitalization of $12.95 million. Protalex employs 2 workers across the globe.

How can I contact Protalex?

Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The company can be reached via phone at 215-862-9720 or via email at [email protected]


MarketBeat Community Rating for Protalex (PRTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Protalex (OTCMKTS:PRTX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Protalex (OTCMKTS:PRTX) Earnings History and Estimates Chart

Earnings by Quarter for Protalex (OTCMKTS:PRTX)

Protalex (OTCMKTS PRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/11/2017Q1 2018($0.04)ViewN/AView Earnings Details
4/5/2017Q3 2017($0.04)ViewN/AView Earnings Details
1/12/2017Q2 2017($0.03)ViewN/AView Earnings Details
10/17/2016Q1 2017($0.04)ViewN/AView Earnings Details
7/15/2016Q4 2016($0.07)($0.06)ViewN/AView Earnings Details
4/12/2016Q3 2016($0.07)($0.06)ViewN/AView Earnings Details
1/7/2016Q2 2016($0.07)($0.08)ViewN/AView Earnings Details
10/13/2015Q1 2016($0.06)($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Protalex (OTCMKTS:PRTX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Protalex (OTCMKTS:PRTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Protalex (OTCMKTS PRTX)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Protalex (OTCMKTS PRTX) News Headlines

Source:
DateHeadline
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune ThrombocytopeniaProtalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia
finance.yahoo.com - January 18 at 11:12 AM
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITPProtalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP
finance.yahoo.com - November 14 at 6:59 AM
Protalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune ThrombocytopeniaProtalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia
finance.yahoo.com - October 27 at 11:31 AM
Heres What Protalex Inc. Just Told Us With Its Latest ReleaseHere's What Protalex Inc. Just Told Us With Its Latest Release
www.benzinga.com - September 8 at 7:18 AM
Heres Where Protalex Announcement Fits Into Development PictureHere's Where Protalex Announcement Fits Into Development Picture
finance.yahoo.com - September 7 at 7:53 AM
Heres Where Protalex Announcement Fits Into Development PictureHere's Where Protalex Announcement Fits Into Development Picture
finance.yahoo.com - September 7 at 7:53 AM
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITPProtalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP
finance.yahoo.com - August 30 at 8:09 AM
Protalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune ThrombocytopeniaProtalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune Thrombocytopenia
finance.yahoo.com - August 17 at 3:21 PM
Protalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITPProtalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITP
finance.yahoo.com - August 2 at 6:50 AM
Protalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITPProtalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITP
finance.yahoo.com - August 2 at 6:50 AM
Protalex Inc (PRTX.PK)Protalex Inc (PRTX.PK)
www.reuters.com - March 22 at 7:30 AM
Protalex Significantly Strengthens Global Intellectual Property Portfolio for Proprietary Immunomodulatory TherapeuticProtalex Significantly Strengthens Global Intellectual Property Portfolio for Proprietary Immunomodulatory Therapeutic
au.finance.yahoo.com - March 13 at 9:40 AM
Protalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune ThrombocytopeniaProtalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia
uk.finance.yahoo.com - February 21 at 5:32 PM
PROTALEX INC Files SEC form 10-K, Annual ReportPROTALEX INC Files SEC form 10-K, Annual Report
biz.yahoo.com - July 15 at 4:09 PM

SEC Filings

Protalex (OTCMKTS:PRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Protalex (OTCMKTS:PRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Protalex (OTCMKTS PRTX) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.